Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing resting dyspnea, syncope, or signs and symptoms of acute deterioration, such as cardiac failure, referred to as acute decompensated aortic stenosis (ADAS). As we all know, optimal medical treatment in these cases is limited, with poor prognosis at hospital discharge, 30 days and one year. 

This analysis included 276 patients with ADAS; 150 received TAVR within ≤22 days after hospitalization and the rest, beyond this period. 

The primary outcome was hospitalization for cardiac failure or all-cause mortality.

The groups were comparable: mean patient age 84, 63% men, 53% hypertensive, 35% had coronary artery disease, 5% had PCI within 90 days prior TAVR, 26% had diabetes, 58% kidney function deterioration, 23% COPD and estimated glomerular filtration rate (eGFR) was 55 ml/min. Mean EuroSCORE was 6,5% and 3% required cardiopulmonary support.

Mean ejection fraction was 55%; 15% presented ejection fraction <30%. There were no differences in aortic valve area, gradients, velocity or presence of mitral or tricuspid regurgitation. 40% of patients presented stage >2 deterioration. 

Read also: EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients.

Mean time to TAVR was 14 days in ≤22 day patients and 33 days in the >22 group. 

There were no differences in valve type or hospital evolution. 

Patients were followed up to 4,6 (3,6–5,7) years. The primary outcome was seen in 58% of patients. Time to TAVR (for every 5-day delay) was significantly associated to the primary outcome (hazard ratio [HR], 1,09 [CI 95%, 1,03–1,14]; P=0,002). Also, >22 days to TAVR was associated to higher risk of adverse events (HR 1,48 [CI 95%, 1,09–2,03]; P=0,013).

Read also: Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes.

The was a significant link between the primary outcome and the presence of syncope, COPD, stroke, stage >2 and the need for cardiopulmonary support.

Conclusion

In patients with acute decompensated aortic stenosis, a longer wait to TAVR was associated to increased risk of events at mid-term. 

Original Title: Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis.

Reference: Michael McKenna, et al. Circ Cardiovasc Interv. 2025;18:e014915. DOI: 10.1161/CIRCINTERVENTIONS.124.014915.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...